There are really two aspects to this. First of all, we not only have to introduce these new emerging technologies when they work— and they've been properly assessed and shown to work significantly and to be cost-effective—but we also have to develop a culture whereby we stop doing things that are not working. The problem with that is we need to better evaluate what works and what doesn't work. We tend to focus clinical research on the evaluation of new technologies, or new drugs, or new practices, but I think we also have to support clinical research that's evaluating what we're currently doing so that we can stop doing what's not efficient, what's not cost-effective, and what doesn't work.
In our patient-oriented research strategy, we really focus on, as I said, implementation and intervention research, on the one hand, ensuring that we change the behaviour and we modify practice. We also want to increase our capacity to do clinical research and evaluate what we are currently doing, what we call cost-effectiveness research, which is what works best and what's most cost-effective. That, I believe, is certainly the type of research that provinces are very interested in and are willing to invest in with us, because they see the direct benefit. I think there's a direct benefit for patients as well. It's a culture of evaluation that we have to develop.